Tendency of isolated bacteria from infections in abdominal surgery during theperiod from April 2005 to March 2006 were investigated in a multicenter study in Japan, and the following results were obtained.
In this series, 384 strains including 18 strains of Candida spp. were isolated from 161 (70.3%) of 229 patients with surgical infections. One hundred and ninty-five strains were isolated from primary infections, and 171 strains were isolated from postoperative infections. From primary infections, aerobic Gram-negative bacteria and aerobic Gram-positive bacteria were predominant, while aerobic Gram-positive bacteria were predominant from postoperative infections. The isolation rate of aerobic Gram-positive bacteria, such as Enterococcus spp. and Staphylococcus aureus were higher from both types of infections. Among anaerobic Gram-positive bacteria, the isolation rate of Peptostreptococcus spp. was the highest from both types of infections. Among aerobic Gramnegative bacteria, Escherichia coli was the most predominantly isolated from primary infections, followed by Pseudomonas aeruginosa, Klebsiella spp. in this order, and from postoperative infections, E. coli was the most predominantly isolated, followed by Klebsiella pneumoniae and P. aeruginosa.
Among anaerobic Gram-negative bacteria, the isolation rate of Bacteroides fragilis group was the highest from both primary and postoperative infections.
In this series, we noticed no vancomycin-resistant Gram-positive cocci, nor multidrug-resistant P. aeruginosa. But cefazolin-resistant E. coil producing extended spectrum β-lactamase was seen in 5.0 per cents. We should be carefully followed up the facts that the increasing isolation rates of B. fragilis group and Bilophila wadsworthia which were resistant to both penicillins and cephems.

View full abstract

We determined the susceptibility of bacteria which were isolated from the patients with respiratory infections between January and October 2005, to tosufloxacin and other fluoroquinolones. A total of 900 isolate including 300 Streptococcus pneumoniae, 100 Streptococcus pyogenes, 100 Moraxella catarrhalis, 200 Haemophilus influenzae, 100 Klebsiella pneumoniae and 100 Pseudomonas aeruginosa were tested. Tosufloxacin, gatifloxacin, levofloxacin, moxifloxacin, ciprofloxacin and prulifloxacin were used as the test antimicrobials.
Tosufloxacin, gatifloxacin and moxifloxacin were potent antibiotics tested for the antibacterial activity against Streptococcus including penicillin-resistant S. pneumoniae; the MIC₉₀ were 0.12-0.5μg/mL. Fluoroquinolones exerted the potent antibacterial activity against M.catarrhalis and H.influenzae; the MIC₉₀ of fluoroquinolones tested were ≤0.06μg/mL. Tosufloxacin, ciprofloxacin and prulifloxacin showed to be more active against K. pneumoniae and P aeruginosa, but parts of some strains wereresistant.
These results indicate that tosufloxacin has the potent antibacterial activity against major organisms detected from patients with respiratory infections. Since it was approved in 1990, tosufloxacin was considered to be useful as a therapeutic antimicrobial for the treatment of respiratory infections.

View full abstract

Antimicrobial susceptibilities for fosfomycin (FOM), cephalexin, cefpodoxime, cefdinir, cefditren, ampicillin, sulbactam/ampicillin, imipenem (IPM), panipenem, meropenem (MEPM), biapenem, levofloxacin (LVFX), gatifloxacin, pazufloxacin, prulifloxacin and sulfamethoxazole/trimethoprim were determined by an agar dilution method using Mueller-Hinton agar (MHA) in Escherichia coli, Klebsiella spp., Serratia marcescens, Citrobacter spp., Enterobacter spp. and Proteus mirabilis, which were isolated from patients in 2003-2004. Those for FOM were determined by the agar dilution methods using MHA containing glucose-6-phosphate (G6P) under aerobic conditions, MHA under anaerobic conditions and nutrient agar under aerobic conditions. Those for FOM, LVFX, IPM and MEPM were also determined by an Etest method.
The results by the agar dilution method showed that carbapenems had good antibacterial activities in all isolates, whereas MIC ranges for other antimicrobials were broad.
Our results showed that the agar dilution method for FOM using MHA containing G6P under aerobic conditions provided reliable MICs in E. coli, which agreed with data previously reported.
The results by the agar dilution method for LVFX, IPM and MEPM showed the high rate of agreement compared with those by the Etest method. In E. coli, the results for FOM by the agar dilution method using MHA containing G6P showed the high rate of agreement compared with the Etest results, although the rate was affected by bacterial species and culture conditions in various ways.

View full abstract

We examined the clinical evaluation of biapenem (BIPM) for febrile neutropenia in patients with hematological disorders. BIPM was administrated by drip infusion when fever developed over 37.5°C with a neutrophil counts lower than 1000/μl. The underlying diseases were acute myelogenous leukemia in 16 cases, acute lymphocytic leukemia in 1, malignant lymphoma in 14, myelodysplastic syndrome in 1, aplastic anemia in 1. Microbiologically documented infections were found in 3 cases (9.1%) before treatment. Clinical effect was excellent in 9 cases, good in 11, fair in 6, poor in 7. Factors associated with efficacy rate were concomitant use of granulocytecolony stimulating factor, duration of neutropenia and neutrophil counts at day 3 of day after start of the therapy. No serious adverse events were observed in all cases, although one case developed exanthema. In conclusion, these results confirmed the efficacy and safety of BIPM for febrile neutropenia in patients with hematological disorders.

View full abstract